吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Nov 9 2017

Full Issue

Potential HHS Pick's Ties To Pharma Raise Questions About Trump's Mission To Curb High Prices

Alex Azar served at Eli Lilly for a decade, including five years as president of its U.S. Lilly USA, LLC unit.

Alex Azar, a former pharmaceutical company executive, is U.S. President Donald Trump's top pick to run the Department of Health and Human Services, two sources with knowledge of the confidential process said on condition of anonymity on Wednesday. Azar served at Eli Lilly for a decade, including five years as president of its U.S. Lilly USA, LLC unit. (Abutaleb, 11/8)

Azar, who worked at Eli Lilly & Co., would be the administration鈥檚 point person on running -- or dismantling -- Obamacare, the health program enacted by Trump鈥檚 predecessor that insures millions of Americans. He will also oversee Medicare and Medicaid, along with dozens of public health programs and sub-agencies. Trump is in Asia for an extended trip and could still change his mind before a replacement is officially named. At Lilly, Azar ran U.S. operations. Trump has been highly critical of the drug industry, saying that companies are 鈥済etting away with murder鈥 and threatening to use the federal government鈥檚 buying power to bring down prices. However, he鈥檚 taken no concrete action yet to do so. (Edney, 11/8)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, August 5
  • Tuesday, August 4
  • Monday, August 3
  • Friday, July 31
  • Thursday, July 30
  • Wednesday, July 29
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF